4:35 PM
 | 
Jan 04, 2013
 |  BC Extra  |  Company News

GlycoVaxyn, Janssen in vaccine deal

GlycoVaxyn AG (Schlieren, Switzerland) and the Janssen Pharmaceuticals Inc. subsidiary of Johnson & Johnson (NYSE:JNJ) will use GlycoVaxyn's bio-conjugation technology to develop a multivalent bacterial vaccine. Under the three-year deal, GlycoVaxyn and...

Read the full 149 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >